Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, Taylor-Harding B, Tanaka H, Orsulic S, Junza A, Yanes O, Muñoz-Pinedo C, Palomero L, Pujana MÀ, Perales JC, Viñals F.
Lahiguera Á, et al. Among authors: tanaka h.
EMBO Mol Med. 2020 Jun 8;12(6):e11217. doi: 10.15252/emmm.201911217. Epub 2020 May 13.
EMBO Mol Med. 2020.
PMID: 32400970
Free PMC article.